Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Encochleated Amphotericin B · MAT2203

Small molecule · Cytotoxic, directed at ergosterol · developed by Matinas BioPharma Nanotechnologies

Phase 3 Most advanced trial (none active)

MTNB Developer

3 Registered trials

What is Encochleated Amphotericin B?

Encochleated Amphotericin B (MAT2203) is an orally bioavailable nanoparticle formulation of the antifungal antibiotic amphotericin B, encapsulated in lipid-based cochleate crystals. It binds ergosterol in fungal cell membranes, causing depolarization and cell rupture. It is studied for vulvovaginal candidiasis and cryptococcal infections.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MAT2203, cAMB
Drug type: Small molecule
Targets: ergosterol
Mechanism: Cytotoxic, directed at ergosterol
Pathways: fungal cell membrane depolarization, cell membrane permeability alteration
Therapy area: Infectious disease
Developer: Matinas BioPharma Nanotechnologies, Inc. (MTNB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05541107	Phase 3	Cryptococcal Meningitis	Unknown	MTNB
NCT03167957	Phase 2	Vulvovaginal Candidiases	Withdrawn	MTNB
NCT03196921	Phase 1/2	Cryptococcal Infections	Withdrawn	MTNB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Candidiasis, VulvovaginalCryptococcal InfectionsCryptococcal MeningitisVulvovaginal CandidiasesVulvovaginitisYeast InfectionYeast Infection Vaginal

More from Matinas BioPharma Nanotechnologies

MAT9001 Phase 3 Omega 3 Phase 1/2 Omega 3 pentaenoic acid Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MTNB page.

Follow MTNB, the company behind Encochleated Amphotericin B

See MTNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MTNB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z